News News
News

23rd May 2016 - Ergomed plc (LSE AIM: ERGO) announces acquisition of Haemostatix Ltd.
Ergomed is a profitable UK-based group dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs. Miroslav Reljanovic MD, Chief Executive Officer of Ergomed plc, said: "The Haemostatix acquisition provides an opportunity to advance the co-development part of our growth strategy through the development of our first wholly-owned development programme. We have confidence from the current preclinical and clinical data that the Haemostatix technology works as an effective haemostat. This, combined with the rapid development and attractive market size, means the acquisition offers great upside potential for Ergomed."

Ben Nichols, Chief Executive Officer of Haemostatix, commented: "I am delighted to be working with Ergomed. With the deep expertise of Ergomed's clinical development team and its global infrastructure, I believe we can accelerate Haemostatix's development programmes for the benefit of all stakeholders. PeproStat and ReadyFlow are both innovative products that have the potential to capture a meaningful share of a $2.5 billion-plus global market."

 

March 2016 - Haemostatix announces successful completion of proof of concept clinical trial of PeproStat Liquid in liver surgery patients. The clinical trial was carried out by four UK hospitals and generated safety and efficacy data in 20 patients undergoing liver resections. The human trial data support the extensive pre-clinical studies indicating a rapid and effective mode of action, alongside the benefits of ease of use and blood-free composition. PeproStat is composed of a peptide-based coagulant formulated in a ready-to-use solution. A further round of investment was made by share-holders on completion of the recruitment phase of the trial.

 

29th June 2015 - Haemostatix's Peptide Dendrimer Coagulant awarded First Prize in the Royal Society of Chemistry Emerging Technologies Competition
29th June 2015 - Haemostatix's Peptide Dendrimer Coagulant awarded First Prize in the Royal Society of Chemistry Emerging Technologies Competition The Emerging Technologies Competition is an annual innovation event organised by the Royal Society of Chemistry. Now in its third year, the Competition accelerates the commercialisation of the most impactful ideas in healthcare, energy and sustainability, and materials. The competition is Europe-wide with a £20,000 first prize, and is backed by multinational partner companies such as GlaxoSmithKline, Croda, Procter & Gamble, Pfizer, AstraZeneca, GE Healthcare, Schlumberger and Lubrizol. The final of the Emerging Technologies Competition 2015 was held in London on 29 June.

Pictured from left to right : RSC Industry Manager, Steve Pleasance, Haemostatix's Research Manager Dr Renata Zbozien, inventor of the Peptide Dendrimer; Haemostatix's CEO, Dr Ben Nichols; Sherry Coutu CBE, serial entrepreneur.
Credit: Royal Society of Chemistry / MPP Image Creation.



 

November 2014 - Haemostatix announces a further internal financing round to support continued clinical development of its lead product PeproStat Liquid, a new class of coagulant/haemostat for surgical bleeding. The company is also investing in a pipeline of new formulations, each targeted at different surgical indications.

 

28th May 2014  New class of coagulant gets go ahead for clinical trial
Haemostatix Ltd announced today that it has received authorisation from the UK regulator, MHRA, to commence a clinical trial of its lead product, PeproStat™. PeproStat is the first of a new class of peptide-based coagulant, or 'haemostat', designed to control bleeding during surgery. Haemostats are used to limit blood loss; to maintain a clear surgical field and to reduce operating time. The leading product on the market is the enzyme thrombin with sales of over $US 1 billion. Thrombin is typically extracted from human donor or bovine blood, and many formulations require preparation prior to use, a disadvantage in surgery if urgent action is required. Haemostatix's product, PeproStat, is designed to address these limitations with a ready-to-use liquid formulation manufactured from blood-free ingredients. In addition, pre-clinical studies indicate that PeproStat has a faster mode of action compared to thrombin, clearly an advantage when controlling bleeding. The technology behind PeproStat is based on a short peptide sequence that binds to the patient's own blood-clotting protein fibrinogen in situ, to form a fibrin-like clot.

The clinical trial will take place at three major hospitals in the UK and is scheduled to complete by the end of 2014. The trial will involve liver surgery patients, and will include an assessment of efficacy.

Dr. Ben Nichols, Haemostatix' CEO, commented that PeproStat offered potential benefits to both patients and surgical teams, and will be a highly competitive alternative to thrombin. He also added that demand for haemostats was growing, and that recent product and company acquisitions were creating new opportunities in the market.

 

Wellcome Trust and investors back clinical development of new haemostat to control surgical bleeding
31st  October 2012- Haemostatix Ltd, a biopharmaceutical company, announced today that it has received an additional £1.4 million Translation Award from the Wellcome Trust to continue development of its innovative haemostat technology. The funding coincides with a further £800,000 investment from Albion Ventures, Catapult Venture Managers, Spark Ventures, Esperante, Nesta, the Lachesis Fund, The University of Leicester and private share-holders. The new funds will enable Haemostatix to progress its lead product, PeproStat, into clinical trials.

PeproStat is a new class of peptide-based haemostat that controls bleeding by binding to the blood protein, fibrinogen, to rapidly form a clot. Haemostats are used by surgeons to manage problematic bleeding and to reduce time in the operating theatre during surgery.  Current haemostatic products may be limited by a slow onset of action as well as a lack of 'ready-to-use' formulations. Additionally leading brands are based on an enzyme, thrombin, that is extracted from human donor blood. PeproStat has been designed to overcome these limitations, and the clinical trial will test the product's safety and effectiveness in man.

Dr Ben Nichols, CEO of Haemostatix, commented: "There is a real need for rapid acting, ready-to-use haemostats that are safe and cost-effective, and we believe our technology can deliver these benefits to surgeons and their patients. This Award and the share-holder investment, will enable us to generate more data to support the translation process from research to patients."

Dr Richard Seabrook, Head of Business Development at the Wellcome Trust, said: "Improved control of bleeding is vital for safe and effective surgical procedures. We are pleased to offer our continued support to this project and look forward to seeing the technology advance towards clinical use."

Haemostatix is based at BioCity Nottingham in the City's new Creative Quarter. The company was originally a spin-out from the University of Leicester and continues to collaborate with the University on fundamental research to underpin its product development programme

 

Haemostatix Ltd secures further investment in new haemostat for surgery 13th June 2011 -  Haemostatix Ltd, a biopharmaceutical company, announced that it has received an investment of £250,000 from Esperante to support development of its innovative haemostat technology. This is the third round of funding the Company has secured in the last 12 months. Haemostats are used by surgeons to manage problematic bleeding and to reduce time in the operating theatre during surgery. The products are applied in the form of sprays, gels or pads, and typically contain the enzyme thrombin, which promotes blood clotting, as the active ingredient.

Haemostatix has developed a new class of active ingredient based on a peptide that binds to another blood clotting protein, fibrinogen, instantly forming a clot.  Dr Ben Nichols, CEO of Haemostatix, commented: "There is a real need for rapid acting, ready-to-use haemostats that are safe and cost-effective, and we believe our technology can deliver these benefits to surgeons and their patients."

Haemostatix is based at Nottingham's BioCity and was originally a spin-out from Leicester University

 

Wellcome Trust and investors back development of new surgical haemostat
5th November 2010
- Haemostatix Ltd, a biopharmaceutical company, announced today that it has received a £409,000 Translation Award from the Wellcome Trust to support development of its innovative haemostat technology. The funding coincides with an additional £459,000 investment from Spark Ventures, Catapult Venture Managers, NESTA, the Lachesis Fund and Leicester University as well as new investor, Nottingham's Mobius Technology Ventures.

Haemostats are used by surgeons to manage problematic bleeding and to reduce time in the operating theatre during surgery. The products are applied in the form of sprays, gels or pads, and typically contain the enzyme thrombin, which promotes blood clotting, as the active ingredient.

Haemostatix has developed a new class of active ingredient based on a peptide that binds to another blood clotting protein, fibrinogen, instantly forming a clot.

Dr Ben Nichols, CEO of Haemostatix, commented: "There is a real need for rapid acting, ready-to-use haemostats that are safe and cost-effective, and we believe our technology can deliver these benefits to surgeons and their patients. We have received a lot of interest from pharmaceutical companies, and this Award and the investment, will enable us to generate more data to support the commercialisation process."

Dr Richard Seabrook, Head of Business Development at the Wellcome Trust, said: "Bleeding is a major cause of mortality during trauma and control of bleeding during surgery is essential to the outcome of procedures. If successful, a new haemostat that bypasses the need for thrombin has the potential to make a huge impact on healthcare and the Wellcome Trust is pleased to support this project."

Haemostatix is based at Nottingham's BioCity and was originally a spin-out from Leicester University